Previous 10 | Next 10 |
Savara ([[SVRA]] +0.6%) announces that the first patient has been dosed in the company's late-stage trial testing its drug molgramostim in patients with autoimmune pulmonary alveolar proteinosis ((aPAP)), a rare lung disease.The trial is a 48-week, randomized, double-blind, placebo-...
The IMPALA-2 trial will evaluate the efficacy and safety of molgramostim nebulizer solution (molgramostim) in aPAP, a rare lung disease with no approved pharmacological treatment options Key learnings from the Phase 2/3 IMPALA trial informed the Phase 3 IMPALA-2 trial design...
Savara failed a key phase 3 trial in aPAP. It is now trying again, with some design changes. The company has decent funds and some analyst interest. For further details see: Savara: They Failed Once, But They Are Trying Again
Savara's (SVRA) molgramostim, in phase 3 for a rare lung disease, has deep commercial potential, leading Oppenheimer to reiterate an outperform rating and raise its price target from $4 to $5.That implies an upside of 199%.Patient randomization in the IMPALA 2 trial is expected to begin this ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT. ...
Savara (SVRA): Q1 GAAP EPS of -$0.13 misses by $0.03.As of March 31, 2021, Savara had cash, cash equivalents, and short-term investments of approximately $192.7 million and debt of approximately $25 million.Press Release For further details see: Savara EPS misses by $0.03
Cash Balance of ~$193M; Company Estimates it is Sufficiently Capitalized through 2025 Clinical Trial Site Activation Process Underway for Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aP...
Chiasma (CHMA) +39% on Q1 results.Athenex (ATNX) +31% on Kuur Therapeutics acquisition.Ault Global Holdings (DPW) +30% on preliminary Q1 results.iBio (IBIO) +26% after resolving Fraunhofer USA lawsuitBig 5 Sporting Goods Corporation (BGFV) +22% on Q1 results.DAVIDsTEA...
Are These The Best Penny Stocks To Buy Right Now? Penny stocks are an interesting type of investment choice. I say this because, on the one hand, you’re buying into mostly start-up phase companies. So the potential for long-term gains would theoretically be higher. But on the oth...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks across all sectors have been popular with investors active on Reddit’s r/WallStreetBets subreddit. But, one area, in particular, they’ve found many of their favorites has been in the biotech spa...
News, Short Squeeze, Breakout and More Instantly...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...
2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...